Sleep Medicine Reviews
Volume 4, Issue 1 , Pages 57-99 , February 2000

Narcolepsy: genetic predisposition and neuropharmacological mechanisms: REVIEW ARTICLE

References 

  1. Gazette des Hôpitaux. 1880;53:626–628
  2. ICSD Chairman . International classification of sleep disorders. Diagnostic and coding manual. Diagnostic Classification Steering Committee, Thorpy MJ, Rochester, MN: American Sleep Disorders. 1990;
  3. Riehl J, Choi S, Mignot E, Nishino S. Changes with age in severity of cataplexy and in sleep/wake fragmentation in narcoleptic Doberman pinschers. Sleep. 1999;22(S):S3
  4. Billiard M, Besset A, Cadilhac J. The clinical and polygraphic development of narcolepsy. In Guilleminault C, Lugaresi E (eds). Sleep/wake disorders: natural history, epidemiology and longterm evolution. New York: Raven Press. 1983;171–185
  5. Sonka K, Tafti M, Billiard M. Narcolepsy and ageing. In Smiru S, Frauceschi M, Ferini-Stambi L (eds). Sleep and Aging, Milano: Masson. 1991;181–186
  6. Guilleminault C. Narcolepsy Syndrome. In Kryger MH, Roth R, Dement WC (eds). Principles and Practice of Sleep Medicine. Philadelphia: W. B. Saunders Company. 1994;549–561
  7. Aldrich M. The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology. 1996;46:393–401
  8. Hublin C, Kaprio J, Partinene M, Koskenvuo M, Heikkila K, Koskimies S. The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Ann Neurol. 1994;35:709–716
  9. Tashiro T, Kambayashi T, Hishikawa Y. An epidemiological study of narcolepsy in Japanese. In: The 4th International Symposium on Narcolepsy; 1994; Tokyo, Japan. 1994;13:
  10. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 1998;50 (Suppl 1):S16–S22
  11. Guilleminault C, Mignot E, Dement WC, Grumet FC. Familial patterns of narcolepsy. Lancet. 1989;335:1376–1379
  12. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997;52:27–78
  13. Baker T, Foutz A, Neyman V, Dement W. Canine model of narcolepsy: genetic and developmental determinants. Exp Neurol. 1982;75:729–742
  14. Mignot E, Wang C, Rattazzi C, Gaiser C, Lovtt M, Guilleminault C. Genetic linkage of autosomal recessive canine narcolepsy with an immunoglobulin μ chain switch-like segment. Proc Natl Acad Sci USA. 1991;88:3475–3478
  15. Cederberg R, Nishino S, Dement WC, Mignot E. The Stanford narcoleptic canine colony: twenty years of breeding history. Vet Rec. 1998;142:31–36
  16. Riehl J, Nishino S, Cederberg R, Dement WC, Mignot E. Development of cataplexy in genetically narcoleptic Dobermans. Exp Neurol. 1998;152:292–302
  17. Nishino S, Tafti M, Reid MS, Shelton J, Siegel JM, Dement WC. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of narcolepsy. J Neurosci. 1995;15:4806–4814
  18. Nishino S, Honda K, Riehl J, Okura M, Mignot E. Neuronal activity in the cholinoceptive basal forebrain of freely moving narcoleptic dobermans. Neuroreport. 1998;9:3653–3661
  19. Tafti M, Nishino S, Aldrich MS, Liao W, Dement WC, Mignot E. Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in a canine model. J Neurosci. 1996;16:4588–4595
  20. Ohayon MM, Priest RG, Caulet M, Guilleminault C. Hypnagogic and hypnopompic hallucinations: pathological phenomena?. Br J Psychiatry. 1996;169:459–467
  21. Ondze B, Lubin S, Lavandier B, Kohler F, Mayeux D, Billiard M. Frequency of narcolepsy in the population of a French ««Department»». J Sleep Res. 1998;7 (Suppl 2):193
  22. Roth B. Narcolepsy and Hypersomnia.. Basel: Karger. 1980;
  23. Dement WC, Carskadon M, Ley R. The prevalence of narcolepsy II. Sleep Res. 1973;2:147
  24. Solomon P. Narcolepsy in Negroes. Dis Nerv Sys. 1945;6:179–183
  25. Honda Y. Census of narcolepsy, cataplexy and sleep life among teenagers in Fujisawa city. Sleep Res. 1979;8:191
  26. Lavie P, Peled R. Narcolepsy is a rare disease in Israel. Sleep. 1987;10:608–609
  27. Westphal C. Eigenthümliche mit Einschläfen verbundene Anfälle. Arch Psychiat. 1877;7:631–635
  28. Billiard M, Pasquie-Magnetto V, Heckman M, Carlander B, Besset A, Zachariev Z. Family studies in narcolepsy. Sleep. 1994;17(Suppl):S54–S59
  29. Lankford DA, Wellman JJ, O»Hara C. Postraumatic narcolepsy in mild to moderate closed head injury. Sleep. 1994;17:S25–S28
  30. Orellana C, Villemin E, Tafti M, Carlander B, Beset A, Billiard M. Life events in the year preceding the onset of narcolepsy. Sleep. 1994;17:S50–S53
  31. Charron D. Molecular basis of human leukocyte antigen class II disease associations. Adv Immunol. 1990;48:107–159
  32. Honda Y, Doi Y, Juji T, Satake M. Positive DR2 as a prerequisite for the development of narcolepsy. Folia Psychiatr Neurol Jpn. 1984;38:360
  33. Matsuki K, Honda Y, Satake M, Juji T. HLA in Narcolepsy in Japan. In Honda Y, Juji T (eds). HLA in Narcolepsy. Berlin: Springer-Verlag. 1988;58–75
  34. Langdon N, Welsh KI, Van Dam M, Vaughan RW, Parkes D. Genetic markers in Narcolepsy. Lancet. 1984;2:1178–1180
  35. Billiard M, Seignalet J, Besset A, Cadihac J. HLA-DR2 and narcolepsy. Sleep. 1986;9:149–152
  36. Neely S, Rosenberg R, Spire J, Antel J, Arnason B. HLA antigens in narcolepsy. Neurology. 1987;37:1858–1860
  37. Matsuki K, Grumet FC, Lin X, Guilleminault C, Dement WC. DQ rather than DR gene marks susceptibility to narcolepsy. Lancet. 1992;339:1052
  38. Honda Y, Matsuki K. Genetic aspects of narcolepsy. In Thropy M (ed). Handbook of sleep disorder. New York: Marcel Dekker, Inc. 1990;217–234
  39. Mueller-Eckardt G, Meier-Ewert K, Schendel D, Reinecker F, Multhoff G, Muller-Eckardt C. HLA and narcolepsy in a German population. Tissue Antigens. 1986;28:163–169
  40. Montplaisir J, Poirier G. HLA in Narcolepsy in Canada. In Honda Y, Juji T (eds). HLA in Narcolepsy. Berlin: Springer-Verlag. 1988;97–107
  41. Roth B, Nevsimalova S, Sonka K, Docekal P, Schulz H, Geisler P. A study of occurrence of HLA DR2 in 124 narcoleptics: clinical aspects. Arch Suiss Neurol et de Psychiat. 1988;139:41–51
  42. Honda Y, Matsuki K. Genetic aspects of narcolepsy. In Thorpy M (ed). Handbook of sleep disorder. New York: Marcel Dekker, Inc. 1990;217–234
  43. Mignot E, Hayduk R, Grumet FC, Black J, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. 1997;20:1012–1020
  44. Lin L, Kuwata S, Tokunaga K, Sasaki T, Honda Y, Juji T. Analysis of HLA class II genes by single-strand conformation polymorphisms in narcolepsy. In Tsuji K, Aizawa M, Sasasuki T (eds). HLA 1991. Proceedings of the Eleventh International Histocompatibility Workshop and Conference. New York: Oxford University Press. 1992;333–335
  45. Kwon OJ, Peled N, Miller K, Pillar G, Peled R, Lavie P. HLA class II analysis in Jewish Israeli narcoleptic patients. Hum Immunol. 1995;44:199–202
  46. Fogdell A, Hillert J, Sachs C, Olerup O. The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele. Tissue Antigens. 1995;46:333–336
  47. Mignot E, Lin X, Arrigoni J, Macaubas C, Olive F, Hallmeyer J. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in caucasian and black Americans. Sleep. 1994;17:S60–S67
  48. Fernandez-vina M, Gao X, Moraes M, Moraes J, Salatiel I, Miller S. Alelles at four HLA class II loci determined by oligonucleotide hybridization and their associations in five ethnic groups. Immunogenetics. 1991;34:299–312
  49. Fernandez-Vina M, Moraes JR, Moraes ME, Miller S, Stasny P. HLA class II haplotypes in Amerindians and in black North and South Americans. Tissue Antigens. 1991;38:235–237
  50. Lin L, Jin L, Kimura A, Carrington M, Mignot E. DQ microsatellite association studies in three ethnic groups. Tissue Antigens. 1997;50:507–520
  51. Begovich AB, McClure GR, Suraj VC, Helmuth RC, Fildes N, Bugawan TL. Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. J Immunol. 1992;148:249–258
  52. Mignot E, Kimura A, Lattermann A, Lin X, Yasunaga S, Mueller-Eckhardt G. Extensive HLA Class II studies in 58 non DRB!*15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens. 1997;49:329–341
  53. Ellis M, Hetisimer AH, Ruddy DA, Hansen SL, Kronmal GS, McClelland E. HLA class II haplotype and sequence analysis support a role of DQ in narcolepsy. Immunogenetics. 1997;46:410–417
  54. Pelin Z, Guilleminault C, Rish N, Grumet FC, Mignot E. HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. Tissue Antigens. 1998;51:96–100
  55. Mignot E, Young T, Lin L, Finn L, Palta M. Reduction of REM sleep latency associated with HLA-DQB1*0602 in normal adults. Lancet. 1998;351:727
  56. Schulz H, Geisler P, Pollmächer T, Andreas-Zietz A, Keller E, Scholz S. HLA-DR2 correlates with rapid-eye-movement sleep latency in normal human subjects. Lancet. 1986;2:803
  57. Mignot E, Kimura A, Latterman A, Lin X, Yasunaga S, Mueller-Eckardt G. Extensive HLA Class II studies in 58 non DRB1*15(DR2) narcoleptic patients with cataplexy. Tissue Antigens. 1997;49:329–341
  58. Mignot E, Lin X, Kalil J, George C, Singh S, Billiard M. DQB1-0602 (DQwl) is not present in most non-DR2 caucasian narcoleptics. Sleep. 1992;15:415–422
  59. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 1998;50 (Suppl 1):S16–S22
  60. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA Class II studies in 509 narcoleptic patients. Sleep Res. 1997;26:433
  61. Mignot E, Lin L, Risch N, Honda Y, Fernandez-Vina M, Juji T. Identification of a novel HLA narcolepsy susceptibility subtype, HLA-DQB1*0301. Sleep. 1999;22:S121
  62. Mignot E, Guilleminault C, Grumet FC, Dement WC. Is narcolepsy an autoimmune disease?. In Smirne S, Francesci M, Ferini-Strambi L, Zucconi M (eds). Proceedings of the Third Milano International Symposium, September 18–19 ««Sleep, Hormones, and the Immune System»». Milan: Masson. 1992;29–38
  63. Frederickson S, Carlander B, Billiard M, Link H. CSF immune variable in patients with narcolepsy. Acta Neurol Scand. 1990;81:253–254
  64. Matsuki K, Juji T, Honda Y. Immunological features of narcolepsy in Japan. In Honda Y, Juji T (eds). HLA in Narcolepsy. Berlin: Spinger-Verlag. 1988;150–157
  65. Mignot E, Nishino S, Hunt Sharp L, Arrigoni J, Siegel J, Reid M. Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci. 1993;13:1057–1064
  66. Nishino S, Mignot E. Neurobiology of Narcolepsy. Neuroscientist. 1998;4:133–143
  67. Knecht CD, Oliver JE, Redding R, Selcer R, Johnson G. Narcolepsy in a dog and a cat. J Am Vet Med Assoc. 1973;162:1052–1053
  68. Mitler M, Boysen M, Campbell L, Dement W. Narcolepsy–cataplexy in a female dog. Exp Neurol. 1974;45:332–340
  69. Honda Y. Clinical features of narcolepsy. In Honda Y, Juji T (eds). HLA in narcolepsy. Berlin: Springer-Verlag. 1988;24–57
  70. Dean RR, Kilduff TS, Dement WC, Grumet FC. Narcolepsy without unique MHC class II antigen association: Studies in the canine model. Hum Immunol. 1989;25:27–35
  71. Dutra AS, Mignot E, Puck JM. Establishing FISH methodology to study synthetic regions between canine and human chromosomes. Am J Hum Genet. 1995;57:A112
  72. Faraco J, Lin X, Li R, Hinton L, Lin L, Mignot E. Genetic studies in narcolepsy, a disorder of REM sleep. J Heredity. 1999;90:129–132
  73. Li R, Mignot E, Faraco J, Kadotani H, Cantanese J, Zhao B. Construction and characterization of an eight fold redundant dog genomic bacterial artificial chromosome library. Genomics. 1999;58:9–17
  74. Roehrs T, Zorick FRW, Paxton C, Sicklesteel J, Roth T. Alerting effects of naps in patients with narcolepsy. Sleep. 1986;9:194–199
  75. Thorpy MJ, Goswami M. Treatment of narcolepsy. In Thorpy MJ (ed.). Handbook of Sleep Disorders. New York: Marcel Dekker, Inc. 1990;235–258
  76. Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy–cataplexy. Sleep. 1993;16:444–456
  77. Rogers AE. Problems and coping strategies identified by narcoleptic patients. J Neurosurg Nursing. 1984;16:326–334
  78. American Narcolepsy Association . Stimulant medication survey. The Eye Opener. 1992;1–3
  79. American Sleep Disorders Association . Practice parameters for the use of stimulants in the treatment of narcolepsy. Sleep. 1994;17:348–351
  80. Prinzmetal M, Bloomberg W. The use of benzedrine for the treatment of narcolepsy. JAMA. 1935;105:2051–2054
  81. Alles GA. The comparative physiological actions of d 1-beta-phenylisopropylamines: pressor effects and toxicity. J Pharmacol Exp Ther. 1933;47:339–354
  82. Parkes JD, Fenton GW. Levo(−)amphetamine and dextro(+)amphetamine in the treatment of narcolepsy. J Neurol Neurosurg Psychiatry. 1973;36:1076–1081
  83. Parkes D. Amphetamines and other drugs. In: Sleep and its disorders. London: W.B. Saunders Company. 1985;459–482
  84. Kanbayashi T, Nishino S, Honda K, Shelton J, Dement WC, Mignot E. Differential effects of D- and L-amphetamine isomers on dopaminergic transmission: Implication for the control of alertness in canine narcolepsy. Sleep Res. 1997;26:383
  85. Parkes JD. Amphetamines and alertness. In Guilleminault C, Dement WC, Passouant P (eds). Narcolepsy. New York: Spectrum publication. 1976;643–658
  86. Yoss RE, Daly DD. Treatment of narcolepsy with ritalin. Neurology. 1959;9:171–173
  87. Pawluk LK, Hurwitz TD, Schulter JL, Ullewig C, Mahowald MW. Psychiatric morbidity in narcoleptics on chronic high doses methylphenidate therapy. J Nerv Ment Dis. 1995;183:45–48
  88. Rogers AE, Aldrich MS, Rosenberg AM. Compliance with stimulant medications in patients with Narcolepsy. Sleep. 1996;20:28–33
  89. Iijima S, Sugita Y, Teshima Y, Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep. 1986;9:265–268
  90. Nishino S, Mao J, Sampathkumaran R, Shelton J, Mignot E. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Research Online. 1998;1:49–61. http://www.sro.org/1998/Nishino/49/
  91. Miler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. Sleep. 1994;17:352–371
  92. Fujimori M, Himwich HE. Electroencephalographic analyses of amphetamine and its methoxy derivatives with reference to their sites of EEG alerting in the rabbit brain. Int J Neuropharmac. 1969;8:601–613
  93. Seijun T. Metamphetamine psychosis. In Ellinwood EH, Cohen S (eds). Current Concept on Amphetamine Abuse. Rockville, Naryland: National Institute of Mental Health. 1970;159–161
  94. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiat. 1988;12:695–700
  95. Besset A, Tafti M, Villemine E, Billiard M. Effect du modafinil (300 mg) sur le sommeil, la somnolence et la vigilance du narcoleptique. Neurophysiol Clin. 1993;23:47–60
  96. Boivin DB, Montplaisir J, Petit D, Lambert C, Lubin S. Effect of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol. 1993;16:46–53
  97. US modafinil in narcolepsy multicenter study group . Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol. 1998;43:88–97
  98. Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49:444–451
  99. Brougton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H. Modafinil for the treatment of excessive daytime sleepiness in narcolepsy: a double-blind, placebo-controlled, cross-over trial. Sleep Research. 1998;26:336
  100. Hermant JF, Rambert FA, Deuteil J. Lack of cardiovascular effects after administration of modafinil in conscious monkeys. In French Association des Pharmacologistes Tours; 1991. Fundam Clin Pharmacol. 1991;825
  101. Gold LH, Balster RH. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology. 1996;126:286–292
  102. Edgar DM, Seidel WF, Contreras P, Vaught JL, Dement WC. Modafinil promotes EEG wake without intensifying motor activity in the rat. Can J Physiol Pharmacol. 1994;72:S1:362
  103. Rall TR. Central nervous system stimulants. In Gilman AG, Goodman LS, Rall TW, Murad F (eds). The Pharmacological Basis of Therapeutics, 7th edn. New York: Pergamon Press. 1985;345–382
  104. Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Sys. 1960;21:704–706
  105. Henry GK, Hart RP, Kwentus JA, Sicola MJ. Effects of protriptyline on vigilance and information processing in narcolepsy. Psychopharmacol. 1988;95:109–112
  106. Raynal D. Polygraphic aspects of narcolepsy. In Guillemault CWCD, Passouant P (eds). Narcolepsy. New York: Spectrum publications, Inc. 1976;669–684
  107. Baldessarini RJ. How do antidepressants work?. In Davis JM, Mass JW (eds). The Affective Disorders. Washington, D.C.: American Psychiatric Press. 1983;243–260
  108. Langdon N, Shindler J, Parkes JD, Bandak S. Fluoxetine in the treatment of cataplexy. Sleep. 1986;9:371–373
  109. Montplaisir J, Godbout R. Serotonergic reuptake mechanisms in the control of cataplexy. Sleep. 1986;9:280–284
  110. Schrader H, Bendixen-Markset AC, Treidene HE. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand. 1986;74:297–303
  111. Hishikawa Y, Ida H, Nakai K, Kaneko Z. Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran). J Neuro Sci. 1965;3:453–461
  112. Mitler MM, Shafor R, Hajdukovich R, Timms RM, Browman CP. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep. 1986;9:260–264
  113. Guilleminault C, Raynal D, Takahashi S, Carskdon M, Dement W. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand. 1976;54:71–87
  114. Shapiro WR. Treatment of cataplexy with clomipramine. Arch Neurol. 1975;32:653–656
  115. Nishino S, Arrigoni J, Shelton J, Dement WC, Mignot E. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep. 1993;16:706–712
  116. Schachter M, Parkes JD. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry. 1980;43:171–174
  117. Poceta JS, Hajdukovic R, Mitler MM. Improvement in cataplexy with yohimbine and paroxetine: case report. Sleep Res. 1994;23:304
  118. Guilleminault C, Mancuso J, Salva MAQ, Hayes B, Mitler M, Poirier G. Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep. 1986;9:275–279
  119. Godbout R, Poirier G, Montplaisir J. New treatment for narcolepsy (viloxazine). In Burton SA, Dement WC, Ristanovic R (eds). Narcolepsy, 3rd International Symposium, 1988. San Diego. 1988;79–81
  120. Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology. 1993;113:76–82
  121. Smith M, Parkes J, Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res. 1996;5 (Suppl 1):217
  122. Takahashi S. The action of tricyclics (alone or in combination with methylphenidate) upon several symptoms of narcolepsy. In Guilleminault C, Dement WC, Passouant P (eds). Narcolepsy. New York: Spectrum Publications. 1976;625–638
  123. Koran L, Raghavan S. Fluoxetine for isolated sleep paralysis. Psychomatics. 1993;34:184–187
  124. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with γ-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep. 1986;9:285–289
  125. Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gammahydroxybutyrate in California. West J Med. 1992;156:380–384
  126. Bédard M, Jacques M, Godbout R, Lapierre O. Nocturnal γ-hydroxybutyrate. Clin Neuropharmacol. 1989;12:29–36
  127. Kaitin KI, Kilduff TS, Dement WC. Sleep fragmentation in genetically narcoleptic dogs. Sleep. 1986;9:116–119
  128. Nishino S, Reid M, Dement WC, Mignot E. Neuropharmacology and neurochemistry of canine narcolepsy. Sleep. 1994;17:S84–S92
  129. Guilleminault C. Cataplexy. Narcolepsy (Advances in Sleep Research Vol. 3). 1976;125–143
  130. Siegel JM. Brainstem mechanisms generating REM sleep. In Kryger MH, Roth T, Dement WC (eds). Principles and Practice of Sleep Medicine. Philadelphia: W.B. Saunders Company. 1994;125–144
  131. Baker TL, Dement WC. Canine narcolepsy–cataplexy syndrome: evidence for an inherited monoaminergic–cholinergic imbalance. In McGinty DJ, Drucker-Colin R, Morrison A, Parmeggiani PL (eds). Brain Mechanisms of Sleep. New York: Raven Press. 1985;199–233
  132. Trulson ME, Jacobs BL. Raphe unit activity in freely moving cats: Correlation with level of behavioral arousal. Brain Res. 1979;163:135–150
  133. Aston-Jones G, Bloom FE. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep–waking cycle. J Neurosci. 1981;1:876–886
  134. Miller JD, Farber J, Gatz P, Roffwarg H, German DC. Activity of mesencephalic dopamine and non-dopamine neurons across stages of sleep and waking in the rat. Brain Res. 1983;273:133–141
  135. Trulson M, Preussler DW, Howell GA. Activity of substantia nigra units across the sleep–waking cycle in freely moving cats. Neurosci Lett. 1981;26:183–188
  136. Peet M, Coppen A. The pharmacokinetics of antidepressant drugs: relevance to their therapeutic effect. In Paykel ES, Coppen A (eds). Psychopharmacology of Affective Disorders. Oxford: Oxford University Press. 1979;91–107
  137. Schmidt H, Clark R, Hyman R. Protriptyline: an effective agent in the treatment of narcolepsy–cataplexy syndrome and hypersomnia. Am J Psychiatry. 1977;134:183–185
  138. Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. J Clin Neurophysiol. 1990;7:93–118
  139. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacology. 1997;7 (Suppl 1):S37–S47
  140. Fuller RW, Snoddy HD, Perry KW, Bymaster FP, Wong DT. Importance of duration of drug action in the antagonism of p-chloroamphetamine depletion of brain serotonin-comparison of fluoxetine and chlorimipramine. Biochem Pharmacol. 1977;27:193–198
  141. Ross SB. The central stimulatory action of inhibitors of dopamine uptake. Life Sci. 1979;24:159–168
  142. Sulser F, Mobley PL. Biochemical effects of antidepressants in animals. In Hoffmeister F, Stille G (eds). Psychotropic Agent: Antipsychotics and Antidepressants, Handbook of Experimental Pharmacology. Berlin: Springer–Verlag. 1980;471–490
  143. Nishino S, Fruhstorfer B, Arrigoni J, Guilleminault C, Dement WC, Mignot E. Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. J Pharmacol Exp Ther. 1993;264:1079–1084
  144. Nishino S, Haak L, Shepherd H, Guilleminault C, Sakai T, Dement WC. Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of rapid eye movement sleep. J Pharmacol Exp Ther. 1990;253:1145–1152
  145. Nishino S, Arrigoni J, Valtier D, Miller JD, Guilleminault C, Dement WC. Dopamine D2 mechanisms in canine narcolepsy. J Neurosci. 1991;11:2666–2671
  146. Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel JM, Dement WC. Local administration of dopaminergic drugs into the ventral tegmental area modulate cataplexy in the narcoleptic canine. Brain Res. 1996;733:83–100
  147. Fruhstorfer B, Mignot E, Bowersox S, Nishino S, Dement WC, Guilleminault C. Canine narcolepsy is associated with an elevated number of α2receptors in the locus coeruleus. Brain Res. 1989;500:209–214
  148. Bowersox S, Kilduff T, Faul K, Dement WC, Ciaranello RD. Brain dopamine receptor levels elevated in canine narcolepsy. Brain Res. 1987;402:44–48
  149. Boehme R, Baker T, Mefford I, Barchas J, Dement WC, Ciaranello R. Narcolepsy: cholinergic receptor changes in an animal model. Life Sci. 1984;34:1825–1828
  150. Nissbrandt N, Engberg G, Pileblad E. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra. Naunyn-Schmiedeberg's Arch Pharmacol. 1991;344:16–28
  151. Kraczmar AG, Longo VG, De Carolis S. A pharmacological model of paradoxical sleep: the role of cholinergic and monoaminergic systems. Physiol Behav. 1970;5:175–182
  152. Reid MS, Siegel JN, Dement WC, Mignot E. Cholinergic mechanisms in canine narcolepsy: II. Acetylcholine release in the potine reticular formation is enhanced during cataplexy. Neuroscience. 1994;59:523–530
  153. Reid MS, Tafti M, Geary J, Nishino S, Siegel JM, Dement WC. Cholinergic mechanisms in canine narcolepsy: I. Modulation of cataplexy via local drug administration into pontine reticular formation. Neuroscience. 1994;59:511–522
  154. Baghdoyan HA, Spotts JL, Snyder SG. Simultaneous pontine and basal forebrain microinjection of carbachol suppresses REM sleep. J Neurosci. 1993;13:229–242
  155. Rolls ET, Sanghera MK, Roper-Hall A. The latency of activation of neurones in the lateral hypothalamus and substantia innominata during feeding in the monkey. Brain Res. 1979;1654:121–135
  156. Reid M, Nishino S, Tafti M, Siegel JM, Dement WC, Mignot E. Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcokleptic canines. Exp Neurology. 1998;151:89–104
  157. Aldrich MS, Naylor MW. Narcolepsy associated with lesions of the diencephalon. Neurology. 1989;39:1505–1508
  158. Nishino S, Mao J, Sampathkumaran R, Honda K, Dement WC, Mignot E. Differential effects of dopaminergic and noradrenergic uptake inhibitors on EEG arousal and cataplexy of narcoleptic canines. Sleep Res. 1996;25:317
  159. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994;17:436–437
  160. Villablanca JR, Marcus RJ, Olmstead CE. Effects of caudate nuclei or frontal cortex ablations in cats. II. Sleep–wakefulness, EEG, and motor activity. Exper Neurol. 1976;53:31–50
  161. Kovacevic R, Radulovacki M. Manoamine changes in the brain of cats during slow-wave sleep. Science. 1976;193:1025–1027
  162. Jones BE. Basic mechanisms of sleep–wake states. In Kryger MH, Roth T, Dement WC (eds). Principles and Practice of Sleep Medicine. Philadelphia: W.B. Saunders Company. 1994;145–162
  163. Cirelli C, Pompeiano M, Tononi G. Neuronal gene expression in the waking state: a role for the locus coeruleus. Science. 1996;274:1211–1215
  164. Trulson ME. Simultaneous recording of substantia nigra neurons and voltametric release of dopamine in the caudate of behaving cats. Brain Res Bull. 1985;15:221–223
  165. Brown RM, Goldman PS. Catecholamines in neocortex of rhesus monkeys: regional distribution and ontogenetic development. rain Res. 1977;142:576–580
  166. Wiegand M, Moller AA, Lauer CJ, Stolz S, Schreiber W, Dose M. Nocturnal sleep in Huntington's disease. J Neurol. 1991;238:203–208
  167. Honda K, Riehl J, Mignot E, Nishino S. Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep. Neuroreport. 1999;10:3717–3724
  168. Okura M, Honda K, Riehl J, Mignot E, Nishino S. Roles of diencephalic dopaminergic cell groups in regulation of cataplexy in canine narcolepsy. Sleep. 1999;22S:S1
  169. Bagetta G, De Sarro G, Priolo E, Nistico G. Ventral tegmental area: site through which dopamine D2-receptor agonists evoke behavioural and electrocortical sleep in rats. Br J Pharmacol. 1988;95:860–866
  170. Vogel G. Studies in psychophysiology of dreams III. The dream of narcolepsy. Arch Gen Psychiatry. 1960;3:421–428
  171. Nishino S, Riehl J, Hong J, Kwan M, Honda K, Mignot E. REM sleep, but not cataplexy, is controlled by a 30-minute normal ultradian rhythm in narcoleptic canines. Sleep. 1999;s2
  172. Okura M, Riehl J, Mignot E, Nishino S. Sulipride, D2/D3 antagonist, suppresses cataplexy, but has no effect on REM sleep in the canine narcolepsy model. Sleep Research Online. 1999;2(S):414
  173. Schneider VE, Ziegler B, Maxion H, Badawi M. Kurz- und Langzeiteffekte von Sulpirid auf das nachtschlaf-EEG des Menschen. Arzneim.-Forsch. 1974;24:990–993

PII: S1087-0792(99)90069-2

doi: 10.1053/smrv.1999.0069

Sleep Medicine Reviews
Volume 4, Issue 1 , Pages 57-99 , February 2000

Article Tools